1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer
Lymphoma
Explore 288 assets in Lymphoma →Floatz Rating
C36/100
Confidence
Indicative
Sponsor
Pfizer
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
27High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05567887CT.gov A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies | — | Completed | — | — | — |
NCT03530683CT.gov A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer (this asset) | Pfizer | P1 | C · 36 |
| Vinblastine | Intensity Therapeutics, Inc. | P4 | BBB |
| Prednisolone | The Lymphoma Academic Research Organisation | P4 | BBB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P4 | BBB |
| Bleomycin | Shandong Provincial Hospital | P4 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Vincristine Sulfate | Inhye Ahn | P3 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BB |
| Methotrexate | University of Chicago | P4 | BB |
+42 more in the Lymphoma cohort
Other indications for 1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P2 | CC · 47 |
| ALK-Positive Large B-Cell Lymphoma | — | P2 | CC · 45 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer in Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/1-118-signal-regulatory-protein-human-fusion-protein-with-immunoglobulin-g4-128-proline-human-4-chain-c-region-c-terminal-fragment-dimer-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →